NASDAQ: PCRX · Specialty & Generic Drug Manufacturers
Pacira BioSciences (PCRX) fair value and price range
As of 28 Sep 2026, Faircurve's model values Pacira BioSciences (PCRX) at $25.32 a share. The stock last closed at $25.21, which puts the model's fair value 0.4% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 2 Oct 2026. Pacira BioSciences, Inc.
Faircurve Insights · 28 Sep 2026
Pacira BioSciences, Inc. operates within the United States. The company provides non-opioid solutions for pain management and regenerative health to healthcare professionals and their patients.
Faircurve's model valued Pacira BioSciences, Inc. at $25.32 a share on 28 Sep 2026. This fair value is the midpoint of 2,000 simulations. The previous run on 19 Sep 2026 gave $26.41, so the fair value moved -4.1%. The calibrated range over 63 trading days is $21.24 to $30.87. This range is built from the fair value, as there is no live options data for the stock. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence behind this valuation as low.
The model compares Pacira BioSciences, Inc. with Supernus Pharmaceuticals, Inc., Amneal Pharmaceuticals, Inc., and Lantheus Holdings, Inc. The stock moved around its last eight earnings reports. The median size of these moves, ignoring direction, was 4.2%.
Written from the figures on this page for the 28 Sep 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give PCRX?
The calibrated range for PCRX over 63 trading days is $21.24 to $30.87. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,327 past valuations, refreshed 26 Sep 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $14.75 to $40.42. In 51% of the simulations the fair value came out above the price the model ran on.
How does PCRX compare with similar companies?
The companies in specialty & generic drug manufacturers closest to Pacira BioSciences in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| AMPH Amphastar Pharmaceuticals, Inc. | $25.43 | $26.29 | +3.4% | Low evidence grade |
| COLL Collegium Pharmaceutical, Inc. | $22.02 | $29.48 | +33.9% | Low evidence grade |
| PAHC Phibro Animal Health Corporation | $37.24 | $34.73 | -6.7% | Low evidence grade |
| ANIP ANI Pharmaceuticals, Inc. | $72.18 | $85.27 | +18.1% | Low evidence grade |
| SUPN Supernus Pharmaceuticals, Inc. | $42.38 | $42.72 | +0.8% | Fairly valued |
| INDV Indivior Pharmaceuticals Inc | $35.71 | $36.01 | +0.8% | Low evidence grade |
| AMRX Amneal Pharmaceuticals, Inc. | $20.30 | $18.51 | -8.8% | Fairly valued |
| LNTH Lantheus Holdings, Inc. | $99.96 | $100.31 | +0.4% | Fairly valued |
All specialty & generic drug manufacturer stocks ranked by gap to fair value
When does PCRX report earnings, and how has the stock reacted?
Pacira BioSciences's next earnings report is scheduled for 5 Nov 2026. Companies can move their dates.
How PCRX moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 4.2%.
| Report date | Two session move |
|---|---|
| 4 Aug 2026 | -7.6% |
| 30 Apr 2026 | -2.8% |
| 26 Feb 2026 | -6.6% |
| 6 Nov 2025 | +0.9% |
| 5 Aug 2025 | -2.4% |
| 8 May 2025 | -6.5% |
| 27 Feb 2025 | -5.6% |
| 6 Nov 2024 | +2.4% |
Pacira BioSciences at a glance
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health.
- Market value
- $988M
- Sector
- Healthcare
- Industry
- Specialty & Generic Drug Manufacturers
- Revenue expected, next twelve months
- $781M
- Consensus revenue growth, next fiscal year
- +3.9%
- Analysts with estimates
- 5
- Beta to the US market
- 0.32
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Pacira BioSciences on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 19 Sep 2026 the model's fair value for PCRX was $26.41. As of 28 Sep 2026 it is $25.32, a change of -4.1%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Pacira BioSciences's valuation
Is Pacira BioSciences stock undervalued or overvalued?
Faircurve's model puts PCRX's fair value at $25.32 a share against a last close of $25.21, as of 28 Sep 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is PCRX's fair value?
$25.32 a share as of 28 Sep 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $14.75 to $40.42.
What price range does the model give PCRX?
$21.24 to $30.87 over 63 trading days. Ranges built this way held the price 60% of the time across 4,327 past valuations, refreshed 26 Sep 2026.
When does Pacira BioSciences report earnings next?
The next report is scheduled for 5 Nov 2026. Companies can move their dates.
How much has PCRX moved on past earnings reports?
Across its last 8 reports the median two session move was 4.2%, ignoring direction. The largest was -7.6% around the report of 4 Aug 2026.
How confident is the model in this valuation?
The model's evidence grade for PCRX is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.